Translational Research in Lung Cancer

  • Deepinder Singh
  • Kevin Bylund
  • Yuhchyau Chen
Part of the Medical Radiology book series (MEDRAD)


Translational research has become an important initiative emphasized by the National Institute of Health (NIH) in recent years, with goals of bringing benchtop research to the bedside through clinical trials, and translating clinical trials to the recommended care in clinical practice. Much progress has been made in the translational research of lung cancer. Molecular predictive tumor markers, such as mutation of epidermal growth factor receptor (EGFR), markers of DNA repair (excision repair cross-complementing group 1 gene product [ERCC1]; regulator subunit of ribonucleotide reductase [RRM1]; human MutS homologue 2 [hMSH2], human MutL homologue 1 [hMLH1]), and echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) have been identified to predict response to molecular targeting agents for non-small cell lung cancer (NSCLC). Serum proteomic profiling was found to predict response to EGFR tyrosine kinase inhibitor (TKI) treatment of NSCLC. Serum markers such as chromogranin A (CgA), neuron-specific enolase (NSE), and pro-gastric-releasing peptide (ProGRP) may aid diagnosis, detection of disease progression or recurrence, and monitoring therapy for small cell lung cancer (SCLC). We present two clinical trial designs that are based on preclinical investigations that offer the rationale and hypotheses for taxane-based chemoradiation treatment to maximize chest tumor control and to target distant micrometastasis for stage III NSCLC. While stage III NSCLC in general is associated with >50% chest failure and a median survival of 14–17 months after chemoradiation treatments, the outcome of this translational approach has yielded a 97% in-field tumor control in study U1597, and 32 months overall survival in study U1500.


Epidermal Growth Factor Receptor Small Cell Lung Cancer Epidermal Growth Factor Receptor Mutation Epidermal Growth Factor Receptor Gene Small Cell Lung Cancer Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Amann JM, Lee JW, Roder H et al (2010) Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol 5:169–178PubMedCrossRefGoogle Scholar
  2. Arriagada R, Bergman B, Dunant A et al (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351–360PubMedCrossRefGoogle Scholar
  3. Arriagada R, le Chevalier T, Quoix E et al (1991) ASTRO plenary: effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. Int J Radiat Oncol Biol Phys 20:1183–1190PubMedCrossRefGoogle Scholar
  4. Arteaga CL (2003) ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 284:122–130PubMedCrossRefGoogle Scholar
  5. Barbacid M (1987) Ras genes. Ann Rev Biochem 56:779–827PubMedCrossRefGoogle Scholar
  6. Berendsen HH, de Leij L, Poppema S et al (1989) Clinical characterization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features. J Clin Oncol 7:1614–1620PubMedGoogle Scholar
  7. Berger MS, Gullick WJ, Greenfield C et al (1987) Epidermal growth factor receptors in lung tumours. J Pathol 152:297–307PubMedCrossRefGoogle Scholar
  8. Bepler G, Olaussen KA, Vataire AL et al (2011) ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am J Pathol 178:69–78PubMedCrossRefGoogle Scholar
  9. Bepler G, Sommers KE, Cantor A et al (2008) Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol 3:1112–1118PubMedCrossRefGoogle Scholar
  10. Bhattacharjee A, Richards WG, Staunton J et al (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98:13790–13795PubMedCrossRefGoogle Scholar
  11. Booton R, Ward T, Ashcroft L et al (2007) ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2:902–906PubMedCrossRefGoogle Scholar
  12. Bos JL (1989) Ras oncogenes in human cancer: a review. Cancer Res 49:4682–4689PubMedGoogle Scholar
  13. Boutros T, Chevet E, Metrakos P (2008) Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol Rev 60:261–310PubMedCrossRefGoogle Scholar
  14. Brose MS, Volpe P, Feldman M et al (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997–7000PubMedGoogle Scholar
  15. Brown ER, Shepherd FA (2005) Erlotinib in the treatment of non-small cell lung cancer. Expert Rev Anticancer Ther 5:767–775PubMedCrossRefGoogle Scholar
  16. Ceppi P, Volante M, Novello S et al (2006) ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17:1818–1825PubMedCrossRefGoogle Scholar
  17. Chen HY, Yu SL, Chen CH et al (2007) A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 356:11–20PubMedCrossRefGoogle Scholar
  18. Chen P, Wiencke J, Aldape K et al (1998) Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomark Prev 9:843–847Google Scholar
  19. Chen Y, Gandara D (2006) Molecular staging of non-small cell lung cancer. In: Syrigos KN, Nutting C, Roussos C (eds) Tumors of the chest: biology diagnosis and management. Springer, Heidelberg pp 159–176Google Scholar
  20. Chen Y, Okunieff P (2004) Radiation and third generation chemotherapy. Hematol Oncol Clin N Am 18:55–80CrossRefGoogle Scholar
  21. Chen Y, Pandya K, Feins R et al (2008) Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 71:407–413PubMedCrossRefGoogle Scholar
  22. Chen Y, Pandya KJ, Hyrien O et al (2010) Preclinical and pilot clinical study of docetaxel chemoradiation for stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys (Epub ahead of print: 12 Aug, 2010)Google Scholar
  23. Chen Y, Pandya K, Keng P et al (2001) Schedule dependent pulsed low-dose paclitaxel radiosensitization for thoracic malignancy. Am J Clin Oncol 24:432–437PubMedCrossRefGoogle Scholar
  24. Chen Y, Pandya K, Keng PC et al (2003) Phase I/II clinical trial using pulsed low-dose paclitaxel radiosensitization for thoracic malignancies: a therapeutic approach based on pre-clinical research of human lung cancer cells. Clin Cancer Res 9:969–975PubMedGoogle Scholar
  25. Cobo M, Isla D, Massuti B et al (2007) Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25:2747–2754PubMedCrossRefGoogle Scholar
  26. Cooper WA, Kohonen-Corish MR, Chan C et al (2008) Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small-cell lung cancer and precursor lesions. Histopathology 52:613–622PubMedCrossRefGoogle Scholar
  27. Cordon-Cardo C (1995) Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 147:545–560PubMedGoogle Scholar
  28. Cox G, Jones JL, O’Byrne KJ (2000) Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 6:2349–2355PubMedGoogle Scholar
  29. Curran WJ Jr, Scott C, Langer C et al (2000) Phase III comparison of sequential vs. concurrent chemoradiation for PTS with unresected stage III non-small cell lung cancer (NSCLC) initial report of radiation therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 19:1891Google Scholar
  30. D’Amico TA, Massey M, Herndon JE II et al (1999) A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardio Surg 117:736–743CrossRefGoogle Scholar
  31. Drivsholm L, Paloheimo LI, Osterlind K et al (1999) Chromogranin A, a significant prognostic factor in small cell lung cancer. Br J Cancer 81:667–671PubMedCrossRefGoogle Scholar
  32. Erisman MD, Linnoila RI, Hernandez O et al (1982) Human lung small-cell carcinoma contains bombesin. Proc Natl Acad Sci USA 79:2379–2383PubMedCrossRefGoogle Scholar
  33. Farmer G, Bargonetti J, Zhu H et al (1992) Wild-type p53 activates transcription in vitro. Nature 358:83–86PubMedCrossRefGoogle Scholar
  34. Fontanini G, De Laurentiis M, Vignati S et al (1998) Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I–IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 4:241–249PubMedGoogle Scholar
  35. Franklin WA, Veve R, Hirsch FR et al (2002) Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 29(1 suppl 4):3–14PubMedCrossRefGoogle Scholar
  36. Greatens TM, Niehans GA, Rubins JB et al (1998) Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Crit Care Med 157:1093–1097PubMedCrossRefGoogle Scholar
  37. Fujii T, Toyooka S, Ichimura K et al (2008) ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer 59:377–384PubMedCrossRefGoogle Scholar
  38. Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 trial). J Clin Oncol 21:2237–2246PubMedCrossRefGoogle Scholar
  39. Furuse K, Fukuoka M, Kawahara M et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692PubMedGoogle Scholar
  40. Furuse K, Hosoe S, Masuda N et al (2000) Impact of tumor control on survival in unresectable stage III non-small cell lung cancer (NSCLC) treated with concurrent thoracic radiotherapy (TRT) and chemotherapy (CT). Proc Am Soc Clin Oncol 18(suppl 1) abstr 1893Google Scholar
  41. Gandara DR, Valone FH, Perez EA et al (1991) Rapidly alternating radiotherapy and high dose cisplatin chemotherapy in stage IIIB non-small cell lung cancer. results of a Phase I/II study. Int J Radiat Oncol Biol Phys 20:1047–1052PubMedCrossRefGoogle Scholar
  42. Gautam A, Bepler G (2006) Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res 66:6497–6502PubMedCrossRefGoogle Scholar
  43. Gazdar AF (2007) DNA repair and survival in lung cancer––the two faces of Janus. N Engl J Med 356:771–773PubMedCrossRefGoogle Scholar
  44. Goldie JH (1987) Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy. Semin Oncol 14:1–7PubMedGoogle Scholar
  45. Greenblatt MS, Bennett WP, Hollstein M et al (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855–4878PubMedGoogle Scholar
  46. Gruber C, Hatz R, Reinmiedl J et al (2008) CEA, CYFRA 21–1, NSE, and ProGRP in the diagnosis of lung cancer: a multivariate approach. J Lab Med 32:361–371Google Scholar
  47. Guo NL, Wan YW, Tosun K et al (2008) Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin Cancer Res 14:8213–8220PubMedCrossRefGoogle Scholar
  48. Hartwell L (1992) Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71:543–546PubMedCrossRefGoogle Scholar
  49. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21:3798–3807PubMedCrossRefGoogle Scholar
  50. Holdenrieder S, von Pawel J, Dankelmann E et al (2008) Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Clin Cancer Res 14:7813–7821PubMedCrossRefGoogle Scholar
  51. Hsu HS, Lee IH, Hsu WH et al (2007) Polymorphism in the hMSH2 gene (gISV12–6T > C) is a prognostic factor in non-small cell lung cancer. Lung Cancer 58:123–130PubMedCrossRefGoogle Scholar
  52. Huncharek M, Kupelnick B, Geschwind JF et al (2000) Prognostic significance of p53 mutations in non-small cell lung cancer: a meta-analysis of 829 cases from eight published studies. Cancer Lett 153:219–226PubMedCrossRefGoogle Scholar
  53. Hwang IG, Ahn MJ, Park BB et al (2008) ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer 113:1379–1386PubMedCrossRefGoogle Scholar
  54. Inamura K, Takeuchi K, Togashi Y et al (2009) EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 22:508–515PubMedCrossRefGoogle Scholar
  55. Jorissen RN, Walker F, Pouliot N et al (2003) Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284:31–53PubMedCrossRefGoogle Scholar
  56. Jung CY, Choi JE, Park JM et al (2006) Polymorphisms in the hMSH2 gene and the risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 15:762–768PubMedCrossRefGoogle Scholar
  57. Kamal NS, Soria JC, Mendiboure J et al (2010) MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Clin Cancer Res 16:1206–1215PubMedCrossRefGoogle Scholar
  58. Kim M, Kang HG, Lee SY et al (2010) Comprehensive analysis of DNA repair gene polymorphisms and survival in patients with early stage non-small-cell lung cancer. Cancer Sci 101:2436–2442PubMedCrossRefGoogle Scholar
  59. Kohno T, Yokota J (1999) How many tumor suppressor genes are involved in human lung carcinogenesis? Carcinogenesis 20:1403PubMedCrossRefGoogle Scholar
  60. Kris MG, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149–2158PubMedCrossRefGoogle Scholar
  61. Kumar A, Petri ET, Halmos B et al (2008) Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 26:1742–1751PubMedCrossRefGoogle Scholar
  62. Larsen JE, Pavey SJ, Bowman R et al (2007) Gene expression of lung squamous cell carcinoma reflects mode of lymph node involvement. Eur Respir J 30:21–25PubMedCrossRefGoogle Scholar
  63. Kwak EL, Camidge DR, Clark J et al (2009) Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol 27:15s Abstract 3509CrossRefGoogle Scholar
  64. Lau SK, Boutros PC, Pintilie M et al (2007) Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 25:5562–5569PubMedCrossRefGoogle Scholar
  65. Lee JS, Park K, Kim S et al (2009) A randomized phase III study of gefitinib versus stand ard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J Thorac Oncol 4:S283–S284 Abstract PRS 4Google Scholar
  66. Li J, Li ZN, Yu LC et al (2010) Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy. Lung Cancer 69:116–122PubMedCrossRefGoogle Scholar
  67. Lo YL, Hsiao CF, Jou YS et al (2011) Polymorphisms of MLH1 and MSH2 genes and the risk of lung cancer among never smokers. Lung Cancer 72:280–286Google Scholar
  68. Lord RV, Brabender J, Gandara D et al (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8:2286–2291PubMedGoogle Scholar
  69. Lu Y, Lemon W, Liu PY et al (2006) A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 3:e467PubMedCrossRefGoogle Scholar
  70. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139PubMedCrossRefGoogle Scholar
  71. Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for nonsmall-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388PubMedCrossRefGoogle Scholar
  72. Marino P, Preatoni A, Cantoni A (1995) Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small cell lung cancer. A meta-analysis. Cancer 76:593–601PubMedCrossRefGoogle Scholar
  73. Mascaux C, Iannino N, Martin B et al (2005) The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 92:131–139PubMedCrossRefGoogle Scholar
  74. Mattson K, Holsti LR, Holsti P et al (1988) Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol 24:477–482PubMedCrossRefGoogle Scholar
  75. Mayne ST, Buenconsejo J, Janerich DT et al (1999) Familial cancer history and lung cancer risk in USA non smoking men and women. Cancer Epidemiol Biomarkers Prev 8:1065PubMedGoogle Scholar
  76. Meyerson M, Carbone D (2005) Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. J Clin Oncol 23:3219–3226PubMedCrossRefGoogle Scholar
  77. Mitsudomi T, Hamajima N, Ogawa M et al (2000) Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 6:4055–4063PubMedGoogle Scholar
  78. Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121–128PubMedCrossRefGoogle Scholar
  79. Mitsudomi T, Steinberg SM, Oie HK et al (1991) Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 51:4999–5002PubMedGoogle Scholar
  80. Miyake Y, Kodama T, Yamaguchi K (1994) Pro-gastrin-releasing peptide (31–98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res 54:2136–2140PubMedGoogle Scholar
  81. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957PubMedCrossRefGoogle Scholar
  82. Morris SW, Kirstein MN, Valentine MB et al (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 263:1281–1284PubMedCrossRefGoogle Scholar
  83. Morton RF, Jett JR, McGinnis WL et al (1991) Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. Ann Int Med 115:681–686PubMedCrossRefGoogle Scholar
  84. Ohsaki Y, Tanno S, Fujita Y et al (2000) Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 7:603–607PubMedGoogle Scholar
  85. Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983–991PubMedCrossRefGoogle Scholar
  86. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500PubMedCrossRefGoogle Scholar
  87. Pastorino U, Andreola S, Tagliabue E et al (1997) Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 15:2858–2865PubMedGoogle Scholar
  88. Pfeiffer P, Clausen PP, Andersen K et al (1996) Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer 74:86–91PubMedCrossRefGoogle Scholar
  89. Pollmann M, Parwaresch R, Adam-Klages S et al (2006) Human EML4, a novel member of the EMAP family, is essential for microtubule formation. Exp Cell Res 312:3241–3251PubMedCrossRefGoogle Scholar
  90. Potti A, Mukherjee S, Petersen R et al (2006) A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 355:570–580PubMedCrossRefGoogle Scholar
  91. Potti A, Mukherjee S, Petersen R et al (2011) Retraction: a genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 364:1176PubMedCrossRefGoogle Scholar
  92. Ramalingham SS, Owonikoko TK, Khuri FR (2011) Lung cancer: new biological insights and recent therapeutic advances. Ca Cancer J Clin 61:91–112CrossRefGoogle Scholar
  93. Reed E (1998) Platinum–DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24:331–344PubMedCrossRefGoogle Scholar
  94. Riely GJ, Marks J, Pao W (2009) KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 6:201–205PubMedCrossRefGoogle Scholar
  95. Rodenhuis S, van de Wetering ML, Mooi WJ et al (1987) Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 317:929–935PubMedCrossRefGoogle Scholar
  96. Rosell R, Danenberg KD, Alberola V et al (2004) Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10:1318–1325PubMedCrossRefGoogle Scholar
  97. Rosell R, Moran T, Queralt C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958–967PubMedCrossRefGoogle Scholar
  98. Rusch V, Klimstra D, Venkatraman E et al (1997) Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 3:515–522PubMedGoogle Scholar
  99. Sasaki T, Rodig SJ, Chirieac LR et al (2010) The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 46:1773–1780PubMedCrossRefGoogle Scholar
  100. Sause W, Kolesar P, Taylor S IV et al (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Chest 117:358–364PubMedCrossRefGoogle Scholar
  101. Scartozzi M, Franciosi V, Campanini N et al (2006) Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients. Lung Cancer 53:103–109PubMedCrossRefGoogle Scholar
  102. Schaake-Koning C, van den Bogaert W, Dalesio O et al (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Eng J Med 326:524–530CrossRefGoogle Scholar
  103. Schiller JH, Adak S, Feins RH et al (2001) Lack of prognostic significance of p53 and K-RAS mutations in primary resected non- small-cell lung cancer on e4592: a laboratory ancillary study on an eastern cooperative oncology group prospective randomized trial of postoperative adjuvant therapy. J Clin Oncol 19:448–457PubMedGoogle Scholar
  104. Shaw AT, Yeap BY, Mino-Kenudson M et al (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247–4253PubMedCrossRefGoogle Scholar
  105. Shih CM, Chen CY, Lee IH et al (2010) A polymorphism in the hMLH1 gene (−93G > A) associated with lung cancer susceptibility and prognosis. Int J Mol Med 25:165–170PubMedGoogle Scholar
  106. Simon G, Sharma A, Li X et al (2008) Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 25:2741–2746CrossRefGoogle Scholar
  107. Sinclair WK, Morton RA (1966) X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 29:450–474PubMedCrossRefGoogle Scholar
  108. Skarda J, Fridman E, Pevova P et al (2006) Prognostic value of hMLH1 and hMSH2 immunohistochemical expression in non-small cell lung cancer. A tissue microarray study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 150:255–259PubMedCrossRefGoogle Scholar
  109. Slebos RJ, Kibbelaar RE, Dalesio O et al (1990) K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323:561–565PubMedCrossRefGoogle Scholar
  110. Souglakos J, Boukovinas I, Taron M et al (2008) Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer 98:1710–1715PubMedCrossRefGoogle Scholar
  111. Steels E, Paesmans M, Berghmans T et al (2001) Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18:705–719PubMedCrossRefGoogle Scholar
  112. Sugio K, Ishida T, Yokoyama H et al (1992) Ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 52:2903–2906PubMedGoogle Scholar
  113. Sun Z, Wigle DA, Yang P (2008) Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. J Clin Oncol 26:877–883PubMedCrossRefGoogle Scholar
  114. Taguchi F, Solomon B, Gregorc V et al (2007) Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 99:838–846PubMedCrossRefGoogle Scholar
  115. Tapia FJ, Polak JM, Barbosa AJ et al (1981) Neuron-specific enolase is produced by neuroendocrine tumors. Lancet 1:808–811PubMedCrossRefGoogle Scholar
  116. Thatcher N, Chang A, Parikh P et al (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomized placebo controlled multicenter study (Iressa survival evaluation in lung cancer). Lancet 366:1527–1537PubMedCrossRefGoogle Scholar
  117. Volm M, Efferth T, Mattern J (1992) Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations. Anticancer Res 12:11–20PubMedGoogle Scholar
  118. Westfall JM, Mold J, Fagnan L (2007) Practice-based research-“Blue Highways” on the NIH roadmap. JAMA 297:403–406PubMedCrossRefGoogle Scholar
  119. Woenckhaus M, Stoehr R, Dietmaier W et al (2003) Microsatellite instability at chromosome 8p in non-small cell lung cancer is associated with lymph node metastasis and squamous differentiation. Int J Oncol 23:1357–1363PubMedGoogle Scholar
  120. Wójcik E, Kulpa JK, Sas-Korczyńska B (2008) ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. Anticancer Res 28:3027–3033PubMedGoogle Scholar
  121. Wu Q, Christensen LA, Legerski RJ et al (2005) Mismatch repair participates in error-free processing of DNA interstrand crosslinks in human cells. EMBO Rep 6:551–557PubMedCrossRefGoogle Scholar
  122. Xinarianos G, Liloglou T, Prime W et al (2000) hMLH1 and hMSH2 expression correlates with allelic imbalance on chromosome 3p in non-small cell lung carcinomas. Cancer Res 60:4216–4221PubMedGoogle Scholar
  123. Yamaguchi K, Abe K, Kameya T et al (1983) Production and molecular size heterogeneity of immunoreactive gastrin-releasing peptide in fetal and adult lungs and primary lung tumors. Cancer Res 43:3932–3939PubMedGoogle Scholar
  124. Yang LY, Li L, Jiang H et al (2000) Expression of ERCC1 antisense RNA abrogates gemcitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res 6:773–781PubMedGoogle Scholar
  125. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nature Rev Mol Cell Biol 2:127–137CrossRefGoogle Scholar
  126. Yin Y, Tainsky MA, Bischoff FZ et al (1992) Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937–948PubMedCrossRefGoogle Scholar
  127. Zhang H, Hyrien O, Pandya K et al (2008) Tumor response kinetics after schedule-dependent paclitaxel chemoradiation treatment for inoperable non-small cell lung cancer: a model for low-dose chemotherapy radiosensitization. J Thorac Oncol 3:563–568PubMedCrossRefGoogle Scholar
  128. Zheng Z, Chen T, Li X et al (2007) DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356:800–808PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg  2011

Authors and Affiliations

  1. 1.University of Rochester Medical CenterRochesterUSA

Personalised recommendations